| Dr. Reddy's Wins Attorney Fees From AstraZeneca in Prilosec OTC Case Aaron F. Barkoff submits: By Jim Wasicak and Aaron Barkoff AstraZeneca v. Dr. Reddy's, No. 07–6790 (S.D.N.Y. 2010)Complete Story » seekingalpha.com |
Psychiatric Group to Unveil Guidelines to Curb Conflicts The American Psychiatric Association is set to unveil conflict-of-interest guidelines today for its members. online.wsj.com |
FDA Staff Sees Risk With Avandia FDA staff scientists continued to question the safety of GlaxoSmithKline's diabetes drug Avandia, according to new agency documents. online.wsj.com |
Roche Dominates the Biotech Deal Flow The Burrill Report submits: By Marie Daghlian Roche (RHHBY.PK) was busy striking deals in the last days of summer, a time when much of Europe goes on holiday. The Swiss biopharma’s Ventana Medical Systems is acquiring California-based diagnostics startup BioImagene for $100 million. Complete Story » seekingalpha.com |
NuPathe Trades at Discount to IPO Price with Near-Term FDA Filing Mike Havrilla submits:NuPathe (NASDAQ:PATH) completed its initial public offering (IPO) on 8/6/10 at $10 per share for 5 million shares of common stock, raising $43 million in net proceeds. The Company's stock is currently trading at a 20% discount at $8 per share with a market cap of $116 million and expects to submit a New Drug Application (NDA) through the 505(b)(2) pathway, representing a novel formulation of a previously approved drug compound.NuPathe ended 2Q10 with $51.5 million in cash/equivalents, which includes net proceeds received from the IPO in early August. The Company reported a net loss of $5.6 million during 2Q10, including $3.3 million for research & development (R&D).Complete Story » seekingalpha.com |